PD-1 knockout T cell therapy - CELLBIOTECH

Drug Profile

PD-1 knockout T cell therapy - CELLBIOTECH

Latest Information Update: 30 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CELLBIOTECH
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 12 Aug 2016 Cell Biotech and Peking University plan a phase I trial for Prostate cancer (Hormone refractory) in China (Parenteral) (NCT02867345)
  • 11 Aug 2016 Preclinical trials in Solid tumours in South Korea (Parenteral) before August 2016
  • 11 Aug 2016 Cell Biotech and Peking University plan a phase I trial for Renal cell carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT02867332)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top